Figure 2: mCuMVTT-RBM induces high levels of specific antibodies with high avidity against RBD and Spike proteins of SARS-CoV-2
A, Vaccination regimen D0/14 or D0/28 and bleeding schedule. B, RBD-specific IgG titer for the groups vaccinated with CuMVTT as a control or mCuMVTT-RBM on days 7, 14, 21, 28, 35 and 42 measured by ELISA OD450. C, Log OD50 of RBD-specific IgG titer for the group vaccinated with mCuMVTT-RBM on days 7, 14, 21, 28, 35 and 42 (Data from B). D, Spike-specific IgG titer for the groups vaccinated with CuMVTT as a control or mCuMVTT-RBM on days 7, 14, 21, 28,3 5 and 42 measured by ELISA OD450. E, Log OD50 of spike-specific IgG titer for the group vaccinated with mCuMVTT-RBM on days 7, 14, 21, 28, 35 and 42 (Data from D). F, Avidity of RBD-specific IgG titer in mice vaccinated with mCuMVTT-RBM using D0/14 vaccination regimen, sera were treated with PBST or 7M Urea. G, Avidity of RBD-specific IgG titer in mice vaccinated with mCuMVTT-RBM using D0/28 vaccination regimen, sera were treated with PBST or 7M Urea. H, Avidity index of RBD-specific IgG in mice vaccinated with mCuMVTT-RBM using D0/14 vaccination regimen, sera were treated with PBST or 7M Urea. L, RBD-specific IgG titer for the group vaccinated with mCuMVTT-RBM on days 42 and 134. M, Spike-specific IgG titer for the group vaccinated with mCuMVTT-RBM on days 42 and 134. Statistical analysis (mean ± SEM) using Students t-test , n=10. One representative of 3 similar experiments is shown. The value of p <0.05 was considered statistically significant (*p <0.01, **p <0.001, ***p <0.0001).